Part, Chapter, Paragraph
1 I, 2. 10. 1| populations based on their genomic risk profile. The upcoming
2 I, 2. 10. 1| factors of diseases such as genomic variants. The occurrence
3 I, 2. 10. 1| can only be used if the genomic risk stratification shows
4 I, 2. 10. 1| based on the individual genomic profile.~So far healthcare
5 III, 10. 2. 4| populations based on their genomic risk profile (Lunshof et
6 III, 10. 2. 4| factors of diseases such as genomic variants. Nonetheless, the
7 III, 10. 2. 4| can only be used if the genomic risk stratification shows
8 III, 10. 2. 4| mutations at the functional genomic unit level, and to better
9 III, 10. 2. 4| entities;~· the concept of a genomic variant being in individuals
10 III, 10. 2. 4| potential of individual genomic profiling: i.e., the concurrent
11 III, 10. 2. 4| concurrent detection of multiple genomic variants that have been
12 III, 10. 2. 4| individual genotype status on all genomic variants increases or decreases
13 III, 10. 2. 4| screening based on individual genomic profiling;~· the impact
14 III, 10. 2. 4| drug targets~· the role of genomic determinants not only within
15 III, 10. 2. 4| obesity);~· the role of genomic determinants as “necessary
16 III, 10. 2. 4| from “genetic test” to “genomic variant” to “genome-based
17 III, 10. 2. 4| possible to assess multiple genomic and protein differences
18 III, 10. 2. 4| deriving from statistics, genomic research, the family history,
19 III, 10. 2. 4| family history, individual genomic variants and the individual
20 III, 10. 2. 4| incomplete and misleading if genomic knowledge is excluded.~ ~
21 III, 10. 2. 4| risks based on individual genomic profiling and may then implement
22 III, 10. 2. 4| surveillance, the upcoming genomic knowledge may require fundamental
23 III, 10. 2. 4| Donnell CJ (2004): Emerging Genomic Technologies and Analytic
